BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

APD209: Phase IIa data

A U.K. Phase IIa trial in 7 evaluable cancer patients showed that APD209 for 8 weeks led to a major response, defined as an increase of >=4% in quadriceps muscle size and/or a >=10% increase...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >